Posted on May 13, 2021 by TMS Clinics Australia

The Federal Government has approved funding of transcranial magnetic stimulation for treatment-resistant depression

Professor Paul Fitzgerald, Co-founder and Medical Director of TMS Clinics Australia, and Professor of Psychiatry at Epworth Healthcare/The Epworth Clinic, has been a leading TMS researcher for 20 years. His understanding of the benefits of TMS therapy for treatment-resistant depression is what lead him to commit himself to advocating for funding to ensure treatment could be accessed by everyone who needs it. The budget announcement is welcome news to our patients, and to all of us at TMS Clinics Australia.


What does this mean?

It means that the government recognises the benefits of TMS therapy for treatment-resistant depression and is willing to provide funding to make treatment more widely accessible. When an MBS item number becomes available, it will significantly reduce out of pocket costs for patients who do not have coverage from a participating health fund.


As of 1 November 2021, new items for Repetitive Transcranial Magnetic Stimulation (rTMS) therapy services have been added to the Medicare Benefits Schedule (MBS) for eligible patients with diagnosed medication-resistant major depressive disorder, more information on eligibility can be found here.


It is important you speak with your healthcare provider about your treatment. If TMS is deemed suitable, do not delay contacting TMS Clinics Australia – we can assist with identifying funding options and helping you to access treatment when you need it.


If you want to be kept up to date on funding or other TMS news, your can subscribe on the Contact page.